Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Nurix Therapeutics (NRIX) announced its upcoming participation at the AACR 2025 Annual Meeting in Chicago, presenting research through two oral and two poster presentations. The company will showcase preclinical data from its DEL-AI platform and several degrader programs.
The oral presentations will focus on: 1) DEL-AI's proteome-wide in silico screening using machine learning foundation models, and 2) selective, orally bioavailable Aurora A degraders for cancer treatment. The poster presentations will highlight: 1) NRX-0305, a pan-mutant BRAF degrader showing broad preclinical efficacy and brain penetrance, and 2) NX-5948, a CNS-penetrant catalytic BTK degrader that challenges conventional CNS drug design principles.
Nurix Therapeutics (NRIX) ha annunciato la sua partecipazione imminente all'AACR 2025 Annual Meeting a Chicago, presentando ricerche attraverso due presentazioni orali e due poster. L'azienda mostrerà dati preclinici dalla sua piattaforma DEL-AI e diversi programmi di degrader.
Le presentazioni orali si concentreranno su: 1) screening in silico su larga scala del proteoma di DEL-AI utilizzando modelli fondamentali di apprendimento automatico, e 2) degrader di Aurora A selettivi e bioavailable per via orale per il trattamento del cancro. Le presentazioni poster metteranno in evidenza: 1) NRX-0305, un degrader pan-mutante di BRAF che mostra una vasta efficacia preclinica e penetranza cerebrale, e 2) NX-5948, un degrader catalitico di BTK penetrante nel SNC che sfida i principi convenzionali del design dei farmaci per il SNC.
Nurix Therapeutics (NRIX) anunció su próxima participación en la AACR 2025 Annual Meeting en Chicago, presentando investigaciones a través de dos presentaciones orales y dos pósters. La empresa mostrará datos preclínicos de su plataforma DEL-AI y varios programas de degradadores.
Las presentaciones orales se centrarán en: 1) el cribado in silico a nivel del proteoma de DEL-AI utilizando modelos de aprendizaje automático, y 2) degradadores de Aurora A selectivos y bio disponibles por vía oral para el tratamiento del cáncer. Las presentaciones de póster destacarán: 1) NRX-0305, un degradador pan-mutante de BRAF que muestra una amplia eficacia preclínica y penetración en el cerebro, y 2) NX-5948, un degradador catalítico de BTK que penetra en el SNC y desafía los principios convencionales del diseño de fármacos para el SNC.
Nurix Therapeutics (NRIX)는 시카고에서 열리는 AACR 2025 Annual Meeting에 참여할 예정이며, 두 개의 구두 발표와 두 개의 포스터 발표를 통해 연구 결과를 발표할 예정입니다. 이 회사는 DEL-AI 플랫폼과 여러 개의 분해제 프로그램의 전임상 데이터를 선보일 것입니다.
구두 발표는 다음과 같은 내용을 중심으로 진행됩니다: 1) 기계 학습 기반 모델을 사용한 DEL-AI의 전단백질 인 실리코 스크리닝, 2) 암 치료를 위한 선택적이고 경구 생체이용 가능한 Aurora A 분해제. 포스터 발표는 다음을 강조합니다: 1) 광범위한 전임상 효능과 뇌 침투성을 보여주는 pan-mutant BRAF 분해제 NRX-0305, 2) 기존의 CNS 약물 설계 원칙에 도전하는 CNS 침투성 촉매 BTK 분해제 NX-5948.
Nurix Therapeutics (NRIX) a annoncé sa prochaine participation à la AACR 2025 Annual Meeting à Chicago, présentant des recherches à travers deux présentations orales et deux posters. L'entreprise mettra en avant des données précliniques de sa plateforme DEL-AI et de plusieurs programmes de dégradateurs.
Les présentations orales porteront sur : 1) le criblage in silico à l'échelle du protéome de DEL-AI utilisant des modèles fondamentaux d'apprentissage automatique, et 2) des dégradateurs d'Aurora A sélectifs et bio-disponibles par voie orale pour le traitement du cancer. Les présentations de posters mettront en lumière : 1) NRX-0305, un dégradateur pan-mutant de BRAF montrant une large efficacité préclinique et une pénétration cérébrale, et 2) NX-5948, un dégradateur catalytique de BTK pénétrant dans le SNC qui remet en question les principes conventionnels de conception des médicaments pour le SNC.
Nurix Therapeutics (NRIX) hat seine bevorstehende Teilnahme an der AACR 2025 Annual Meeting in Chicago angekündigt, wo es Forschungsergebnisse in zwei mündlichen und zwei Posterpräsentationen vorstellen wird. Das Unternehmen wird präklinische Daten von seiner DEL-AI-Plattform und mehreren Degrader-Programmen präsentieren.
Die mündlichen Präsentationen konzentrieren sich auf: 1) das proteomweite in silico Screening von DEL-AI unter Verwendung von maschinellen Lernmodellen, und 2) selektive, oral bioverfügbare Aurora A Degrader zur Krebsbehandlung. Die Posterpräsentationen werden hervorheben: 1) NRX-0305, ein pan-mutant BRAF Degrader, der eine breite präklinische Wirksamkeit und Gehirnpenetration zeigt, und 2) NX-5948, ein zerebrales, katalytisches BTK Degrader, das die konventionellen Prinzipien des CNS-Arzneimitteldesigns in Frage stellt.
- Development of innovative drug discovery platform DEL-AI showing technological advancement
- Progress in multiple drug candidates: NRX-0305 and NX-5948 showing promising preclinical results
- Potential breakthrough in CNS drug development with NX-5948
- All presented data is still in preclinical stage, indicating long pathway to commercialization
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting, which will be held from April 25-30, 2025, in Chicago, IL.
Oral Presentation Details:
Title: DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models
Presenting author: Paul Novick, Ph.D.
Session title: Innovative Approaches in Drug Discovery: Novel Leads, Degraders, and AI-Driven Solutions
Session date and time: Monday, April 28, 2025, 2:30 PM – 4:30 PM CST
Abstract ID: 3762
Title: Identification of selective, orally bioavailable Aurora A degraders for treatment of pediatric and adult cancers
Presenting author: Ryan Rountree, Ph.D.
Session title: Degraders and Glues
Session date and time: Tuesday, April 29, 2025, 2:30 PM – 4:30 PM CST
Abstract ID: 6379
Poster Presentation Details:
Title: NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers
Presenting authors: Alexandra ‘Sasha’ Borodovsky, Ph.D.
Session title: Degraders and Glues 2
Session date and time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CST
Abstract ID: 1651
Title: NX-5948 is a CNS-penetrant catalytic Bruton’s tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs
Presenting authors: Wylie Palmer, Ph.D.
Session title: Targeted Protein Degradation
Session date and time: Wednesday, April 30, 2025, 9:00 AM – 12:00 PM CST
Abstract ID: 7003
About DEL-AI
DEL-AI is Nurix’s discovery platform which employs advanced machine learning to enable all aspects of Nurix’s discovery engine, starting with DNA encoded library (DEL) hit-finding and degrader design, followed by automated chemistry synthesis and direct-to-biology screening and optimization, to rapidly generate degraders and degrader antibody conjugates (DACs) as new chemical entity drug candidates. By leveraging hundreds of billions of DEL compound binding signatures derived from thousands of DEL affinity screens collected from a diverse set of highly validated protein targets, our DEL-AI platform can prospectively identify binders as starting points for drug discovery for virtually any pharmaceutically relevant target.
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).
About NRX-0305
NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating potent anti-tumor activity in multiple cell line-derived and patient-derived xenograft disease models representing Class I, Class II and Class III B-RAF mutations. Anti-tumor activity was also observed in the setting of CNS disease and treatment-resistance, suggesting the potential for utility across a broad range of solid tumor types
About Aurora A Kinase
Aurora A kinase (AURKA) is an oncogene frequently overexpressed in adult solid tumors, hematologic malignancies, and pediatric cancers. Several AURKA inhibitors are effective in preclinical tumor models, but this activity has failed to translate into clinical efficacy. To address the limitations of inhibitors, Nurix has designed bifunctional targeted protein degraders of AURKA that enable removal of both enzymatic and scaffolding functions.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the planned timing for the provision of updates and findings from Nurix’s preclinical studies, including Nurix’s intention to present preclinical data from its DEL-AI platform and degrader programs at the AACR 2025 Annual Meeting, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K for the year ended November 30, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What will Nurix Therapeutics (NRIX) present at AACR 2025?
What is the significance of NRX-0305 in NRIX's research pipeline?
How does Nurix's NX-5948 degrader innovate CNS drug development?
What is the focus of NRIX's DEL-AI platform presentation?
